Shots:
- Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, to expand its hematology portfolio into bleeding disorders
- As per the deal, Incyte will acquire Vega for $1.25B upfront, with ~$750M in additional payments upon achievement of sales milestones
- Acquisition will expand Incyte’s hematology portfolio with VGA039, which is being evaluated in the P-III (VIVID-6) trial as prophylaxis for bleeding in pts with every type of von Willebrand disease
Ref: Businesswire | Image: Vega Therapeutics | Press Release
Related News: Incyte Expands Partnership with Genesis Molecular AI to Advance AI-Driven Drug Discovery
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
